CAU
RNAM

Caxton Associates (UK)’s Avidity Biosciences RNAM Stock Holding History

Caxton Associates (UK)’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-442,307
Closed -$31.9M – 969
2025
Q4 		$31.9M Buy
+442,307
New +$28.6M 0.62% 24

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $158M AUM

Caxton Associates (UK)'s RNAM Position: Q1 2026 in Review

Caxton Associates (UK) sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 442,307 shares — an estimated $31.9M sold.

Caxton Associates (UK) first reported a position in RNAM in Q4 2025 and held it in 1 quarter. The position peaked at $31.9M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Caxton Associates (UK) reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Caxton Associates (UK) sold 442,307 Avidity Biosciences shares in Q1 2026, an estimated $31.9M.
  • Caxton Associates (UK) first reported a position in Avidity Biosciences in Q4 2025 and held it in 1 quarter.
  • Caxton Associates (UK)'s Avidity Biosciences position peaked at $31.9M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Caxton Associates (UK)'s 13F filing for Q1 2026, filed 14 May 2026.